Serinus Biosciences
ActiveCombinations therapy by rational design
What it does
Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.
Next to it in Healthcare and bio · AI-driven cancer combination therapy design
- NanograbY Combinator S23
Deliver genes to any cell with AI
- WittGenPlug and Play PnP 2025
GenAI virtual patients to ensure clinical success
- Olio LabsY Combinator S23
Combination therapeutics for the world's toughest diseases
- WhiteLab GenomicsY Combinator W22
Unleashing the potential of DNA and RNA based therapies using AI
- OncoveryCareTechstars TS 2022
OncoveryCare: The First Virtual Cancer Survivorship Clinic
- Pando BioscienceY Combinator W23
Gen-AI Designed Enzymes for Pharmaceutical Innovation
- Persist AIY Combinator W23
Developing long-lasting drug formulations 50% faster
- Mindstate Design LabsY Combinator S21
Programmable biology company for psychoactive effect design